A novel proteoliposomal vaccine elicits potent antitumor immunity in mice.
Therapeutic vaccination against idiotype is a promising strategy for immunotherapy of B-cell malignancies. Its feasibility, however, is limited by the requirement for a patient-specific product. Here we describe a novel vaccine formulation prepared by simply extracting cell-membrane proteins from lymphoma cells and incorporating them together with IL-2 into proteoliposomes. The vaccine was produced in 24 hours, compared with more labor-intensive and time-consuming hybridoma or recombinant DNA methods. The vaccine elicited T-cell immunity in vivo, as demonstrated by secretion of type 1 cytokines. It protected against tumor challenge at doses of tumor antigen 50 to 100 times lower than that previously observed using either liposomes formulated with IL-2 and secreted lymphoma immunoglobulin or a prototype vaccine consisting of lymphoma immunoglobulin conjugated to keyhole limpet hemocyanin. The increased potency justifies testing similar patient-specific human vaccines prepared using extracts from primary tumor samples.
Popescu
Mircea C
MC
XEME Biopharma, Plainsboro, NJ 08536, USA. mpopescu@xemebiopharma.com
Robb
Richard J
RJ
Batenjany
Michael M
MM
Boni
Lawrence T
LT
Neville
Mary E
ME
Pennington
Robin W
RW
Neelapu
Sattva S
SS
Kwak
Larry W
LW
D000818:Animals; D000888:Antibodies, Anti-Idiotypic; D019496:Cancer Vaccines / Q000276:immunology* / Q000494:pharmacology; D005260:Female; D007109:Immunity; D016393:Lymphoma, B-Cell / Q000628:therapy; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D011510:Proteolipids / Q000627:therapeutic use*
D000888:Antibodies, Anti-Idiotypic; D019496:Cancer Vaccines; D011510:Proteolipids; C020485:proteoliposomes